Sammanfattning

Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3 '-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein mu-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TR alpha/TR beta) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.

Nyckelord

μ‐Crystallin; androgen receptor; prostate cancer; PSMA‐PET; thyroid hormone receptor

Publicerad i

International Journal of Cancer
2021, Volym: 148, nummer: 3, sidor: 731-747
Utgivare: WILEY

SLU författare

• Moazzami, Ali

  • Institutionen för molekylära vetenskaper, Sveriges lantbruksuniversitet
    

Globala målen

SDG3 Säkerställa hälsosamma liv och främja välbefinnande för alla i alla åldrar


UKÄ forskningsämne

Cancer och onkologi


Publikationens identifierare

DOI: https://doi.org/10.1002/ijc.33332

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/108709